Results 1 to 10 of about 994,610 (203)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval [PDF]

Journal of Bone Oncology, 2022
Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple
Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck   +8 more
doaj   +3 more sources

Clinicopathologic characteristics, metastasis-free survival, and skeletal-related events in 628 patients with skeletal metastases in a tertiary orthopedic and trauma center [PDF]

World Journal of Surgical Oncology, 2021
Background Skeletal-related events (SREs) due to bone metastases (BM) significantly impact the morbidity and mortality of cancer patients. The present study sought to investigate clinicopathological characteristics, metastasis-free survival (MFS), and ...
Georg Herget, Babak Saravi, Eugenia Schwarzkopf, Mara Wigand, Norbert Südkamp, Hagen Schmal, Markus Uhl, Gernot Lang   +7 more
doaj   +3 more sources

Incidence, Risk Factors, and Survival of Bone Metastases and Skeletal-Related Events in Melanoma Patients: A Systematic Review and Quality Assessment of 29 Studies [PDF]

Journal of Bone Oncology
Background: Skeletal metastases make up 17% of all metastases from advanced-stage melanoma. Bone metastases are associated with increased morbidity and mortality and decreased quality of life due to their association with skeletal-related events (SREs ...
Michelle R. Shimizu, Olaf N. van de Langerijt, Daniel Torres, Tom M de Groot, Olivier Q. Groot   +4 more
doaj   +3 more sources

Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. [PDF]

PLoS ONE, 2019
BackgroundWe conducted a multicenter retrospective analysis to describe the characteristics, frequency of skeletal-related events (SREs), and prognosis of head and neck cancer (HNC) in patients with bone metastases (BM).Patients and methodsThe data of ...
Salvatore Grisanti, Susanna Bianchi, Laura D Locati, Luca Triggiani, Stefania Vecchio, Alberto Bonetta, Cristiana Bergamini, Pierfranco Conte, Mario Airoldi, Marco Merlano, Paolo Carlini, Toni Ibrahim, Ciro Rossetto, Salvatore Alfieri, Paolo Pronzato, Sandro Tonoli, Roberto Maroldi, Piero Nicolai, Carlo Resteghini, Stefano M Magrini, Alfredo Berruti   +20 more
doaj   +3 more sources

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw. [PDF]

Sci Rep, 2023
Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, reduces skeletal-related events (SREs) and is approved for solid tumors with bone metastases.
Fu PA, Shen CY, Yang SR, Lee CH, Chen HW, Lai EC, Chung WP.   +6 more
europepmc   +2 more sources

Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. [PDF]

J Clin Med, 2022
Contemporary information is sparse on the frequency of skeletal-related events (SREs) in multiple myeloma (MM) patients at a population-based level in the era of novel agents.
Kanellias N, Ntanasis-Stathopoulos I, Gavriatopoulou M, Koutoulidis V, Fotiou D, Migkou M, Eleutherakis-Papaiakovou E, Malandrakis P, Bagratuni T, Mavropoulos-Papoudas S, Roussou M, Kastritis E, Moulopoulos LA, Dimopoulos MA, Terpos E.   +14 more
europepmc   +2 more sources

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. [PDF]

J Natl Compr Canc Netw, 2021
BACKGROUND Bone metastases and skeletal-related events (SREs) are a frequent cause of morbidity in patients with metastatic non-small cell lung cancer (mNSCLC).
Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan KA, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH.   +24 more
europepmc   +2 more sources

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events [PDF]

, 2015
Background In a phase III trial in patients with castration-resistant prostate cancer (CRPC) and bone metastases, denosumab was superior to zoledronic acid in reducing skeletal-related events (SREs; radiation to bone, pathologic fracture, surgery to ...
Balakumaran, A., Braun, A., Chi, K.N., Coleman, R.E., Fizazi, K., Klotz, L., Milecki, P., Ng, S., Pittman, K., Smith, M.R., Wang, H., Wei, R.   +11 more
openalex   +5 more sources

The importance of retaining physical functions to prevent skeletal‐related events in multiple myeloma patients with bone disease [PDF]

eJHaem, 2022
This study was undertaken to identify baseline conditions and triggering factors for skeletal‐related events (SRE) in multiple myeloma (MM) patients treated with denosumab.
Hirokazu Miki, Shingen Nakamura, Masahiro Oura, Masafumi Nakamura, Ryohei Sumitani, Kimiko Sogabe, Mamiko Takahashi, Tomoko Maruhashi, Takeshi Harada, Shiro Fujii, Hirofumi Hamano, Masateru Kondo, Naoto Okada, Itsuro Endo, Masahiro Abe   +14 more
doaj   +2 more sources

Clinical benefit of early treatment with bone‐modifying agents for preventing skeletal‐related events in patients with genitourinary cancer with bone metastasis: A multi‐institutional retrospective study [PDF]

International journal of urology, 2019
To evaluate the clinical benefit of bone‐modifying agents and identify the risk factors of skeletal‐related events in patients with genitourinary cancer with newly diagnosed bone metastasis.
Takuya Owari, Makito Miyake, Yasushi Nakai, Shunta Hori, Mitsuru Tomizawa, Kazuki Ichikawa, Takuto Shimizu, Kota Iida, Shoji Samma, Yusuke Iemura, Hitoshi Momose, Chihiro Omori, Takeshi Otani, Masaomi Kuwada, Shuya Hirao, Nobuo Oyama, Yoshinori Nakagawa, Yoshiki Hayashi, Nobumichi Tanaka, Kiyohide Fujimoto   +19 more
openalex   +2 more sources